Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:58:00.584Z.
Calculation as of: 2026-10-06T17:58:00.584Z.
Quote observation: 2026-10-06T17:39:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92121ceff5fa8810ba44f4cfbc32d43134c549094e5f0bfbc79a82dde622c70d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$3.04M
PS Ratio
N/A
TTM Avg
71.18
3Y Avg
73.71
5Y Avg
73.71
Market Cap
$3.01M
PS Ratio
8.41
TTM Avg
15.52
3Y Avg
50.28
5Y Avg
84.84
Market Cap
$3.25M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revelation Biosciences, Inc. (REVB) | $3.05M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.04M | N/A | 71.18 | 73.71 | 73.71 |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.01M | 8.41 | 15.52 | 50.28 | 84.84 |
| IceCure Medical Ltd (ICCM)vs › | $3.13M | 0.79 | 8.88 | 13.52 | 16.08 |
| MBody AI Ltd. (MBAI)vs › | $3.16M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.25M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.27M | N/A | 69.25 | 700.44 | 2108.35 |
| iSpecimen Inc. (ISPC)vs › | $2.77M | 5.94 | 1.16 | 0.59 | 1.24 |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.84M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.46M | N/A | 2.56 | 108.40 | 108.40 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
